EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens

Xirui Xia, Huifang Zhao, Yaxi Li, Xiangyang Long, Xuezhen Liu, Mingyang Bai, Youzhi Tang, Xiangguang Shen, Huanzhong Ding

Poultry Science · 2025

DOI: 10.1016/j.psj.2025.105249 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Poultry Science, 2025. Verfasst von Xirui Xia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Key Laboratory for Veterinary Drug Development and Safety evaluation, College of Veterinary Medicine, South China Agricultural University, …. Hauptthemen laut MEDLINE: Chickens, Mycoplasma gallisepticum, Mycoplasma Infections, Poultry Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycoplasma gallisepticum (M. gallisepticum, MG) is the primary pathogen of chronic respiratory disease (CRD) in chickens and leads to pneumonia and air sacculitis in infected chickens and a corresponding economic loss for the poultry industry. The pleuromutilins have excellent anti-mycoplasmal activity and we evaluated the in vivo activity of a new derivative 22-((4-((2-furan-1-yl)acetamido)phenyl)thio) deoxypleuromutilin (p-furoylamphenmulin) against M. gallisepticum. A plasma pharmacokinetic (PK) study and an in vivo pharmacodynamic (PD) study of p-furoylamphenmulin were performed using an M. gallisepticum-infected chicken model. Based on the PK/PD results, a preliminary recommended dose was calculated. The minimum inhibitory concentration (MIC) of p-furoylamphenmulin against M. gallisepticum was 0.001953125 μg/mL. PK results indicated that the absorption half-life (T1/2ka) in infected chicks was 0.10 h, elimination half-life (T1/2kel) was 4.23 h. The areas under the concentration-time curve at 24 h (AUC24h) for 5, 40, and 80 mg/kg single-dose injections were 1.49, 10.15, and 18.56 μg·h/mL, respectively. The peak concentrations (Cmax) of 5, 40, and 80 mg/kg were 0.56, 5.79, and 9.53 μg/mL, respectively. The PD results indicated that at doses of 70 and 80 mg/kg, the mycoplasmal counts in lungs decreased by 3.39 and 3.28 Log10CFU/mL, respectively, achieving a bactericidal effect. Through PK/PD fitting, the target values corresponding to reducing the lung mycoplasma load by 3 Log10 CFU/mL of AUC24h/MIC and Cmax/MIC were 8288.29 h and 4299.30, respectively, and the calculated dosage using formula (2) was 62.64 mg/kg, under the regimen of intramuscular injection once every 24 h for 3 consecutive days. In addition, the effect of high-dose p-furoylamphenmulin on the relief of air sac lesions was significant. These results provide a basis for developing and applying p-furoylamphenmulin and provide a preliminary medication regimen.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ChickensMycoplasma gallisepticumMycoplasma InfectionsPoultry DiseasesAnti-Bacterial AgentsDiterpenesPolycyclic CompoundsAnimalsPleuromutilinsMicrobial Sensitivity TestsMaleHalf-Life

Stichwörter der Autor:innen

ChickenMycoplasma gallisepticumPK/PDPleuromutilinp-furoylamphenmulin

Substanzen

Anti-Bacterial AgentsPleuromutilinsDiterpenesPolycyclic Compounds

Autor:innen und Institutionen

  • Guangdong Key Laboratory for Veterinary Drug Development and Safety evaluation, College of Veterinary Medicine, South China Agricultural University, 510642 Guangzhou, China.
  • Guangdong Key Laboratory for Veterinary Drug Development and Safety evaluation, College of Veterinary Medicine, South China Agricultural University, 510642 Guangzhou, China. Electronic address: hzding@scau.edu.cn.

Förderung

  • National Key Research and Development Program of China

Zitieren

APA

Xia, X., Zhao, H., Li, Y., Long, X., Liu, X., Bai, M., Tang, Y., Shen, X., & Ding, H. (2025). Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens. Poultry Science. https://doi.org/10.1016/j.psj.2025.105249

Vancouver

Xia X, Zhao H, Li Y, Long X, Liu X, Bai M, et al. Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens. Poultry Science. 2025. doi:10.1016/j.psj.2025.105249

BibTeX
@article{Xia2025,
  author = {Xia, Xirui and Zhao, Huifang and Li, Yaxi and Long, Xiangyang and Liu, Xuezhen and Bai, Mingyang and Tang, Youzhi and Shen, Xiangguang and Ding, Huanzhong},
  title = {Pharmacokinetic/pharmacodynamic relationship of a novel pleuromutilin derivative p-furoylamphenmulin against Mycoplasma gallisepticum in vivo in chickens},
  journal = {Poultry Science},
  year = {2025},
  doi = {10.1016/j.psj.2025.105249}
}
Kostenlos starten →